deucravacitinib · Bristol · NDA 214958
Sotyktu
Earliest generic entry, as listed
11 Feb 2043
Blocked by patent: US 12521390, US 12521390.
Listed patents · 8 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12521390 | product, use U-4451 | 11 Feb 2043 |
| US 12521390 | product, use U-3434 | 11 Feb 2043 |
| US 12734169 | product, use U-3434 | 18 Sep 2040 |
| US 12734169 | product, use U-4452 | 18 Sep 2040 |
| US 10000480 | substance, product | 7 Nov 2033 |
| US 11021475 | use U-3434 | 7 Nov 2033 |
| US RE47929 | substance, product, use U-3434 | 7 Nov 2033 |
| US RE47929 | substance, product, use U-4452 | 7 Nov 2033 |
Exclusivities · 2 unexpired
| I-986 | new indication (3 years) | 6 Mar 2029 |
| NCE | new chemical entity (5 years) | 9 Sep 2027 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 214958 · 001 · RLD | tablet, oral | 6MG | 11 Feb 2043 |